Jul 4, 2017
Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma
C. Borsoi, F. Leonard, Y. Lee, M. Zaid, D. Elganainy, J. F. Alexander, M. Kai, Y. T. Liu, Y. Kang, X. Liu, E. J. Koay, M. Ferrari, B. Godin, K. Yokoi , Cancer Letters , DOI: 10.1016/j.canlet.2017.06.026
The mechanism for improved therapeutic efficacy of the combination therapy with nanoparticle albumin-bound paclitaxel (nAb-PTX) and gemcitabine (gem) for pancreatic ductal adenocarcinoma (PDAC) has been ascribed to enhanced gem transport by nAb-PTX. Here, we used an orthotopic mouse model of gem-resistant human PDAC in which increasing gem transport would not...
Jul 3, 2017
UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression
D. J. Grant, Z. Chen, L. E. Howard, E. Wiggins, A. De Hoedt, A. C. Vidal, S. T. Carney, J. Squires, C. E. Magyar, J. Huang, S. J. Freedland , BMC Cancer , DOI: 10.1186/s12885-017-3463-6
Background: Uridine 5′-diphosphate-glucuronosyltransferase 2B (UGT2B) genes code for enzymes that catalyze the clearance of testosterone, dihydrotestosterone (DHT), and DHT metabolites in the prostate basal and luminal tissue. The expression of the UGT2B15, UGT2B17, and UGT2B28 enzymes has not been evaluated in prostate tissue samples from hormone therapy-naïve patients.Methods: We determined...
Jul 2, 2017
The importance of co-localized resting CD8+ T cells and proliferating tumor cells in gastric cancer
M. Yigitsoy, S. Earle, A. Meier, N. Harder, M. Hale, A. Zuraw, T. Yoshikawa, G. Schmidt, R. Huss, H. I. Grabsch , Cancer Research , DOI: 10.1158/1538-7445.AM2017-3958
Gastric cancer (GC) is the third leading cause of cancer-related death worldwide. With the advent of immunotherapies, there is a need to characterize the phenotype of tumor infiltrating immune cells and co-localized cancer cells. We have shown previously that high density of CD45R0+ T cells is related to better prognosis...
Jul 2, 2017
Formation and merger of H69 and H69AR small cell lung cancer (SCLC) tumor cell clusters (TCCs) in vitro
N. O. Ruprecht, M. Hungerbuehler, P. Kellmann, N. Harder, G. Schmidt, C. Wotzkow, B. Haenni, F. Blank, H. Von Tengg-Kobligk, C. Granzow , Cancer Research , DOI: 10.1158/1538-7445.AM2017-1889
A novel manifestation of tumor cell invasiveness, termed mutual cellular pervasion (MCP), was observed in vitro. It involved TCCs formed by SCLC cells. Suspension cultures of H69 and H69AR cells were grown in flavin-free RPMI 1640 medium with 10% fetal bovine serum as the only source of flavins. Experiments and...
Jun 29, 2017
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas - A Phase 2 Clinical Trial
M. Toulmonde, MD; N. Penel, MD, PhD; J. Adam, MD, PhD; C. Chevreau, MD; J.-Y. Blay, MD, PhD; A. Le Cesne, MD; E. Bompas, MD; S. Piperno-Neumann, MD; S. Cousin, MD; T. Grellety, MD; T. Ryckewaert, MD; A. Bessede, PhD; F. Ghiringhelli, MD, PhD; M. Pulido, MSc; A. Italiano, MD, PhD , JAMA Oncology , DOI: 10.1001/jamaoncol.2017.1617
Importance: There is a strong rationale for treating sarcomas with immunotherapy.Objective: To assess the efficacy and safety of programmed cell death protein 1 (PD-1) targeting in combination with metronomic chemotherapy in sarcomas.Design, Setting, and Participants: This was an open-label, multicenter, phase 2 study of 4 cohorts of patients with advanced...